Table 4.
Proportion of time (%) on antiretroviral agents during follow-up (n=703)
| Antiretroviral agents | Proportion of follow-up time (%); no diabetes (n=571) | Proportion of follow-up time (%); with diabetes (n=132) | P value |
| Mean (SD) | Mean (SD) | ||
| Nucleoside reverse transcriptase inhibitors | |||
| Stavudine | 7.2 (14.6) | 21.1 (26.4) | <0.001 |
| Zidovudine | 5.0 (14.5) | 10.9 (22.8) | 0.011 |
| Didanosine | 3.6 (11.0) | 11.5 (21.7) | <0.001 |
| Lamivudine or emtricitabine | 82.5 (23.1) | 78.8 (23.2) | 0.027 |
| Abacavir | 23.1 (32.7) | 16.3 (26.6) | 0.084 |
| Tenofovir disoproxil fumarate | 51.5 (38.1) | 38.4 (33.4) | <0.001 |
| Protease inhibitors | |||
| Indinavir | 2.1 (7.5) | 6.4 (15.0) | <0.001 |
| Saquinavir | 1.3 (6.5) | 2.3 (9.6) | 0.079 |
| Nelfinavir | 0.6 (3.5) | 2.8 (11.4) | 0.033 |
| Lopinavir | 9.3 (21.1) | 21.1 (29.2) | <0.001 |
| Atazanavir | 38.1 (39.0) | 28.4 (33.5) | 0.021 |
| Darunavir | 3.5 (13.2) | 1.6 (9.1) | 0.007 |